#BiopharmaManufacturing
LightNews LightNews
4040rec.bsky.social
#Hyperscaling #healthcare #datascience #lifesciences #AI #datainterpretation #healthcareindustry #insights #biopharma #diagnostics #pharmaceuticals #healthcareinnovation #agenticworkflows #realtimedata #biopharmaceuticals #biopharmamanufacturing #strategy
pharmaphorum.com/digital/hype...
Hyperscaling healthcare with data science
We need to broaden access to advanced technologies so that, ultimately, every patient can benefit from them. It’s a goal otherwise known as the “hyperscaling of healthcare”.
pharmaphorum.com
June 19, 2025 at 9:50 AM
narrowit.bsky.social
Samsung Biologics Plans KRW 3 Trillion Rights Offering for Expansion Samsung Biologics proposed roughly 2.27 million new...

https://www.narrowit.com/news/samsung-biologics-rights-offering-polypeptide-expansion-2026-08-27
#SamsungBiologics #Polypeptide #RightsOffering #BiopharmaManufacturing
Samsung Biologics Plans KRW 3 Trillion Rights Offering | Narrowit.com
Samsung Biologics plans a KRW 3 trillion rights offering to fund its pending PolyPeptide acquisition and Bio Campus II expansion.
www.narrowit.com
August 28, 2026 at 12:12 AM
narrowit.bsky.social
WuXi Biologics Revenue Rises 18% as Pipeline and Utilization Lift Margins WuXi Biologics reported 11.8 billion yuan of first-half revenue, stronger...

https://www.narrowit.com/news/wuxi-biologics-h1-revenue-margin-backlog-growth-2026-08-25
#WuxiBiologics #Earnings #BiopharmaManufacturing #Backlog
WuXi Biologics H1 Revenue Rises 18% | Narrowit.com
WuXi Biologics reported 11.8 billion yuan in H1 revenue, margin expansion and a $25.1 billion backlog, with adjusted-profit caveats.
www.narrowit.com
August 25, 2026 at 4:17 PM